Related Experiment Video
Updated: Nov 24, 2025

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children
Victoria Lucia Dávila Osorio1, María Asunción Vicente1, Eulalia Baselga1
1Department of Dermatology Hospital Sant Joan de Deu, Barcelona, Spain.
Background:
Mitogen-activated protein kinase inhibitors (MEKi) are currently used for the treatment of central nervous system tumors in children and have shown promising results. Cutaneous adverse effects are among the most common toxicities described in adults, but few studies exist in pediatric patients.
Objective:
We aimed to describe the cutaneous adverse effects associated with MEKi in pediatric patients.
Methods:
A retrospective study was carried out at our pediatric hospital in Barcelona, Spain, in patients undergoing treatment with MEKi.
Results:
Sixty-one children between 1 and 18 years of age were included. All patients developed cutaneous toxicity. Eczema, hair abnormalities, oral aphthae, and paronychia were among the most common cutaneous side effects.
Conclusions:
Recognizing skin toxicity in pediatric patients under treatment with MEKi is essential to establishing appropriate education and therapy, thereby improving treatment tolerability and minimizing avoidable interruptions in treatment.
Related Concept Videos
MAPK Signaling Cascades
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Mitogens and the Cell Cycle
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Pharmacokinetics in Pediatric Patients: Drug Distribution

